Schwab Charles Investment Management Inc. lowered its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 5.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 182,509 shares of the biopharmaceutical company’s stock after selling 10,033 shares during the period. Schwab Charles Investment Management Inc. owned 0.21% of Alnylam Pharmaceuticals worth $9,354,000 as of its most recent filing with the SEC.
Other large investors have also recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. raised its stake in Alnylam Pharmaceuticals by 0.4% in the first quarter. PNC Financial Services Group Inc. now owns 8,685 shares of the biopharmaceutical company’s stock worth $446,000 after buying an additional 36 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in Alnylam Pharmaceuticals by 0.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 111,350 shares of the biopharmaceutical company’s stock worth $4,170,000 after buying an additional 695 shares during the last quarter. Swiss National Bank raised its stake in Alnylam Pharmaceuticals by 0.6% in the first quarter. Swiss National Bank now owns 127,700 shares of the biopharmaceutical company’s stock worth $6,545,000 after buying an additional 800 shares during the last quarter. Pacer Advisors Inc. raised its stake in Alnylam Pharmaceuticals by 19.4% in the first quarter. Pacer Advisors Inc. now owns 9,517 shares of the biopharmaceutical company’s stock worth $488,000 after buying an additional 1,544 shares during the last quarter. Finally, Macquarie Group Ltd. raised its stake in Alnylam Pharmaceuticals by 10.0% in the fourth quarter. Macquarie Group Ltd. now owns 17,755 shares of the biopharmaceutical company’s stock worth $665,000 after buying an additional 1,614 shares during the last quarter. 88.96% of the stock is owned by institutional investors and hedge funds.
Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ ALNY) opened at 78.22 on Friday. Alnylam Pharmaceuticals, Inc. has a 12 month low of $31.38 and a 12 month high of $86.92. The company’s market capitalization is $7.18 billion. The company has a 50-day moving average of $80.94 and a 200 day moving average of $61.92.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.22) by $0.12. Alnylam Pharmaceuticals had a negative return on equity of 45.53% and a negative net margin of 670.81%. The firm had revenue of $15.93 million during the quarter, compared to the consensus estimate of $23.86 million. During the same period in the previous year, the company posted ($1.05) EPS. The firm’s revenue for the quarter was up 82.9% compared to the same quarter last year. Analysts forecast that Alnylam Pharmaceuticals, Inc. will post ($5.23) EPS for the current year.
A number of research firms recently weighed in on ALNY. Morgan Stanley reaffirmed an “equal weight” rating on shares of Alnylam Pharmaceuticals in a report on Monday, July 10th. Stifel Nicolaus reaffirmed a “buy” rating and set a $56.00 price target (up from $47.00) on shares of Alnylam Pharmaceuticals in a report on Thursday. Chardan Capital set a $95.00 price target on shares of Alnylam Pharmaceuticals and gave the company a “buy” rating in a report on Friday, May 5th. BMO Capital Markets initiated coverage on shares of Alnylam Pharmaceuticals in a report on Monday, April 17th. They set an “outperform” rating and a $73.00 price target for the company. Finally, Ladenburg Thalmann Financial Services set a $80.00 price objective on shares of Alnylam Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, May 17th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $81.74.
In other Alnylam Pharmaceuticals news, VP Michael Mason sold 9,375 shares of the stock in a transaction dated Tuesday, May 16th. The shares were sold at an average price of $70.00, for a total transaction of $656,250.00. Following the sale, the vice president now owns 5,625 shares of the company’s stock, valued at approximately $393,750. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Sanofi acquired 297,501 shares of the firm’s stock in a transaction on Wednesday, May 31st. The shares were bought at an average cost of $71.87 per share, for a total transaction of $21,381,396.87. The disclosure for this purchase can be found here. In the last ninety days, insiders sold 64,125 shares of company stock worth $4,325,000. 4.30% of the stock is owned by insiders.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.